Abstracts tagged "Nephritis"

Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…
Abstract Number: 2057 • 2016 ACR/ARHP Annual Meeting
TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling
Sonya Wolf¹, Tamra J. Reed², Chaim O. Jacob³ and J. Michelle Kahlenberg⁴, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine/Div of Rheumatology, USC School of Medicine, Los Angeles, CA, ⁴Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies, immune complex deposition, elevated production of type I interferons (IFNs),…
Abstract Number: 2801 • 2016 ACR/ARHP Annual Meeting
Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus
Laurence S Magder¹, Ali Duarte-Garcia², Erik Barr³ and Michelle Petri⁴, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Tufts Medical Center, Boston, MA, ³Epidemiology, University of Maryland, Baltimore, MD, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains one of the most devastating SLE complications, occurring in over 50% of the patients. It is important to identify clinical conditions…
Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Yuko Sakuma¹, Tatsuo Nagai², Taku Yoshio³ and Shunsei Hirohata⁴, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Jichi Medical University, Tochigi, Japan, ⁴Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 387 • 2015 ACR/ARHP Annual Meeting
Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study
Clovis A Silva¹, Roberta C. Gomes Sr.², Marco F. Silva³, Katia T. Kozu⁴, Eloisa Bonfá⁵, Rosa M R Pereira⁶, Maria Teresa Terreri⁷, Claudia S. Magalhães Sr.⁸, Silvana B. Sacchetti Sr.⁹, Roberto Marini Sr.¹⁰, Melissa Fraga¹¹, Luciana M. Carvalho Sr.¹², Cássia M. Barbosa¹³ and Magda Carneiro-Sampaio Sr.¹⁴, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, São Paulo State University – Faculdade de Medicina de Botucatu, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ¹¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁴Pediatric Allergology and Immunology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Previous retrospective evaluations suggested that age at diagnosis may influence disease expression in terms of initial clinical presentation, pattern of organ involvement and serological…
Abstract Number: 403 • 2015 ACR/ARHP Annual Meeting
Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
Justin Hung Tiong Tan¹, Sook Fun Hoh², Manasita Tanya¹, Lena Das¹, Ma Thin Mar Win³, Yiong Huak Chan³ and Thaschawee Arkachaisri^1,4, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ³Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, ⁴Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore
Background/Purpose: The time to recovery from proteinuria in patients with lupus nephritis (LN) receiving standard treatment has been described in adult, but not in children.…
Abstract Number: 2191 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Vinicius Domingues¹, DENIS WAHL² and Stephane Zuily³, ¹Rheumatology, New York University School Of Medicine, New York, NY, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France
Background/Purpose : Renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their associations with aPL are inconsistent among studies. Therefore our objective…
Abstract Number: 2629 • 2014 ACR/ARHP Annual Meeting
Childhood-Onset and Adult-Onset Systemic Lupus Erythematosus: Distinctions in an Underserved Ethnic Minority Cohort
Rebekah Neal¹, Kimberly DeQuattro², Elizabeth C. Ortiz¹ and Francisco P. Quismorio Jr. ³, ¹Rheumatology, University of Southern California, Los Angeles, CA, ²LAC+USC Medical Center, Los Angeles, CA, ³Div of Rheum & Immun, Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Previous studies suggest differences between childhood-onset SLE (cSLE) and adult onset SLE (aSLE). Whereas the prevalence of nephritis, neuropsychiatric, dermatologic, and hematologic manifestations are…
Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
María Galindo Izquierdo¹, Esther Rodriguez-Almaraz¹, Sabina Perez², José M. Pego-Reigosa³, Jaime Calvo-Alen⁴, Francisco Javier López-Longo⁵, Iñigo Rúa-Figueroa⁶, Alejandro Olivé⁷, Víctor Martínez Taboada⁸, Paloma Vela Casasempere⁹, Mercedes Freire¹⁰, Javier Narváez¹¹, Antonio Fernandez Nebro¹², Jose Rosas¹³, Monica Ibanez Barcelo¹⁴, Esther Uriarte¹⁵, Eva Tomero¹⁶, Antonio Zea¹⁷, Maria Loreto Horcada¹⁸, Vicente Torrente¹⁹, Ivan Castellvi²⁰, Joan Calvet²¹, Raúl Menor Almagro²², Mª Angeles Aguirre²³, Enrique Raya²⁴, Elvira Diez Alvarez²⁵, Tomás Vázquez Rodríguez²⁶, Paloma García de la Peña²⁷, Atusa Movasat²⁸, José Luis Andreu²⁹, Patricia Richi³⁰, Carlos Marras Fernandez-Cid³¹, Carlos Alberto Montilla Morales³², Blanca Hernández-Cruz³³, José Luis Marenco de la Fuente³⁴, Marian Gantes³⁵, Eduardo Ucar³⁶, Juan J. Alegre³⁷, Javier Manero³⁸, Jesús Ibañez Ruán³⁹, Manuel Rodríguez-Gómez⁴⁰, Victor Quevedo⁴¹, José Hernández Beiraín⁴² and Lucía Silva Fernández⁴³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, ³Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Marqués de Valdecilla, Santander, Spain, ⁹Hospital General de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹²Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ¹³Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹⁴H. Son Llatzer, Palma de Mallorca, Spain, ¹⁵Rheumatology, Hospital de Donosti, San Sebastian, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁸Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ²⁰Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Hospital Parc Taulí, Barcelona, Spain, ²²Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, ²³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²⁴Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁵Rheumatology, Leon Hospital, Leon, Spain, ²⁶Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁷Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁸Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁹Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹C/ Salvia 11, H. Arrixaca, Alicante, Spain, ³²Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, ³³Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁴Hospital de Valme. Sevilla, Sevilla, Spain, ³⁵Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ³⁶Hospital de Basurto, Rheumatology, Bilbao, Spain, ³⁷Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³⁸Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ³⁹POVISA, Rheumatology, Vigo, Spain, ⁴⁰Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴³Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…
Abstract Number: 1657 • 2014 ACR/ARHP Annual Meeting
Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Eulalia Armengol¹, Javier Narváez², Helena Borrell¹, Sergi Heredia¹, Milagros Ricse¹, Eva Benavent³, Alex Roset³, Carmen Gomez Vaquero¹, Joan Torras⁴, Francesca Mitjavila³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that usually affects young people. Several reviews have shown that age may have an effect on…
Abstract Number: 2794 • 2013 ACR/ARHP Annual Meeting
Characterisation Of Antigens Driving In Situ Autoantibody Production In Human Lupus Tubulointerstitial Nephritis (TIN)
Andrew Kinloch¹, Scott Henderson¹, Natalya Kaverina², Anthony Chang³, D. James Haddon⁴, Justin Jarrel⁴, Carole Henry Dunand², Patrick C. Wilson⁵, Paul Utz⁴ and Marcus R. Clark⁶, ¹Rheumatology and Knapp Center of Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ³Pathology, University of Chicago, Chicago, IL, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁶Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: We have demonstrated that the degree of tubulointerstitial nephritis (TIN) on diagnostic biopsy predicts progression to renal failure. TIN is associated with tertiary lymphoid…
Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Imelda Balboni¹, David Haddon², Vivian Diep², Cindy Limb² and Paul Utz², ¹Pediatrics, Stanford University School of Medicine, Palo Alto, CA, ²Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…
Abstract Number: 671 • 2012 ACR/ARHP Annual Meeting
Differences in the SLE Clinical Phenotype by Age of Diagnosis
T. Clark Powell¹, Elizabeth E. Brown on behalf of PROFILE², Gerald McGwin Jr.³, Luis M. Vila⁴, Yesenia C. Santiago-Casas⁴, Michelle Petri⁵, Rosalind Ramsey-Goldman⁶, John D. Reveille⁷, Sergio Duran⁸, Sergio M.A. Toloza⁹, Robin L. Brey¹⁰, Agustin Escalante¹¹, Randy Q. Cron¹², Robert P. Kimberly on behalf of PROFILE investigators¹³ and Graciela S. Alarcon¹⁴, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁸UIECD, Guadalajara, Mexico, Guadalajara, Mexico, ⁹Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ¹⁰Medicine/Neurology, UTHSCSA, San Antonio, TX, ¹¹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ¹²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by the presence of antinuclear autoantibodies, complement activation and the formation and…
Abstract Number: 679 • 2012 ACR/ARHP Annual Meeting
ZAP70+ B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis
Elisa Gremese, Barbara Tolusso, Laura Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: To analyze differences in B cells subsets distribution in patients with renal systemic lupus erythematosus (SLE). To define possible cellular biomarkers of active nephritis…
Abstract Number: 2678 • 2012 ACR/ARHP Annual Meeting
Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Teresa Owen¹, Wensheng Wang¹, Dilara McCauley², Laura Strojny¹, Jennifer Hossler¹, Javier Rangel-Moreno³, Michael Kauffman², Sharon Shacham⁴ and Jennifer H. Anolik⁵, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Karyopharm, Therapeutics Inc., Natick, MA, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴Karyopharm Therapeutics Inc., Natick, MA, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Most therapies currently used to treat systemic lupus erythematosus (SLE) and B cell targeted therapies under development do not effectively target plasma cells and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].